Rallybio Corporation
NCM: RLYBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Rallybio Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get RLYB Z-Score →About Rallybio Corporation
Healthcare
Biotechnology
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
📊 Fundamental Analysis
Rallybio Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 484.2% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -15.0%, which indicates that capital utilization is currently under pressure.
At a current price of $8.44, RLYB currently sits at the 69th percentile of its 52-week range (Range: $1.79 - $11.49).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$44.64M
Trailing P/E
--
Forward P/E
-1.56
Beta (5Y)
-1.20
52W High
$11.49
52W Low
$1.79
Avg Volume
144K
Day High
Day Low